Androgen receptor as a target in androgen-independent prostate cancer.

Abstract excerpt

Prostate cancer is dependent on androgen stimulation mediated by the androgen receptor (AR), a member of the steroid hormone receptor family of ligand-dependent nuclear receptors. Most patients respond to standard androgen ablation therapies, but virtually all patients eventually relapse with disease that has been termed hormone-refractory or androgen-independent disease. Efforts to use AR antagonists, such as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Androgen Antagonists
• Share to Anilides
• Share to Antineoplastic Combined Chemotherapy Protocols